Featured Research

from universities, journals, and other organizations

Protein discovery may lead to new treatment to prevent smoking relapse

Date:
October 22, 2012
Source:
Centre for Addiction and Mental Health
Summary:
Scientists have identified a potential new approach to preventing smoking relapse, which occurs frequently in smokers who attempt to quit, despite current treatments.

Scientists at the Centre for Addiction and Mental Health (CAMH) have identified a potential new approach to preventing smoking relapse, which occurs frequently in smokers who attempt to quit, despite current treatments.

"We have developed a protein peptide that may be a new type of highly targeted treatment to prevent smoking relapse," says Dr. Fang Liu, Senior Scientist in CAMH's Campbell Family Mental Health Research Institute and Professor in the Department of Psychiatry at the University of Toronto.

Dr. Liu and her team initially found that nicotine exposure can enhance binding between two types of brain receptors -- a nicotinic receptor and a glutamate receptor. They identified the sites where the two receptors bind together. With this information, they were able to generate a protein peptide to disrupt the binding of the two receptors.

Working with CAMH Senior Scientist Dr. Anh Dzung Le, the peptide was then tested in an animal model of relapse. As anticipated, it had the effect of reducing attempts to seek nicotine.

"These discoveries present an avenue to develop an anti-smoking medication that directly targets the relapse process by focusing on this brain target," says Dr. Liu, whose study was published online in the Journal of Experimental Medicine October 22. "We hope that it will lead to an alternative treatment for smokers who aren't succeeding with current smoking cessation medications." A year after treatment with current medications, only about 20 per cent of people remain abstinent, past research shows.

"As research continues, future steps are to determine how this discovery can be translated into a novel intervention for patients," says Dr. Liu. "We are optimistic that our findings will lead to new options for treatment for smoking, which is the leading preventable cause of disease, disability and premature death in our society."


Story Source:

The above story is based on materials provided by Centre for Addiction and Mental Health. Note: Materials may be edited for content and length.


Journal Reference:

  1. Shupeng Li, ZhaoXia Li, Lin Pei, Anh D. Le, and Fang Liu. The α7nACh–NMDA receptor complex is involved in cue-induced reinstatement of nicotine seeking. Journal of Experimental Medicine, 2012 DOI: 10.1084/jem.20121270

Cite This Page:

Centre for Addiction and Mental Health. "Protein discovery may lead to new treatment to prevent smoking relapse." ScienceDaily. ScienceDaily, 22 October 2012. <www.sciencedaily.com/releases/2012/10/121022113639.htm>.
Centre for Addiction and Mental Health. (2012, October 22). Protein discovery may lead to new treatment to prevent smoking relapse. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/10/121022113639.htm
Centre for Addiction and Mental Health. "Protein discovery may lead to new treatment to prevent smoking relapse." ScienceDaily. www.sciencedaily.com/releases/2012/10/121022113639.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins